Georgia vs Russian Federation: Share of S. aureus infections resistant to methicillin
Georgia
28.3%
in 2022
Russian Federation
17.0%
in 2021
Georgia rank
22nd
Russian Federation rank
25th
Share of S. aureus infections resistant to methicillin over time
- Georgia
- Russian Federation
How they compare
Georgia currently reports 28.3% against 17.0% in Russian Federation, a difference of 11.3%.
That makes Georgia's figure about 1.7 times Russian Federation's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Russian Federation ahead.
Georgia ranks 22nd and Russian Federation ranks 25th of 45 countries.
Russian Federation has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Georgia | Russian Federation | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9.4% | 19.1% | 9.6% | Russian Federation |
| 2020s | 22.7% | 23.0% | 0.2% | Russian Federation |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of s. aureus infections resistant to methicillin, Georgia or Russian Federation?
- Georgia, at 28.3% against 17.0% in Russian Federation as of 2022.
- What is the difference in share of s. aureus infections resistant to methicillin between Georgia and Russian Federation?
- 11.3%, with Georgia ahead.
- How many years of comparable data are there for Georgia and Russian Federation?
- 5 years are reported by both, from 2017 to 2021.
- How do Georgia and Russian Federation rank globally for share of s. aureus infections resistant to methicillin?
- Georgia ranks 22nd and Russian Federation ranks 25th of 45 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of S. aureus infections resistant to methicillin. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%).